2024-2032 年阿黴素市場報告（按應用、配銷通路和地區）

IMARC Group年，全球阿黴素市場規模達13億美元。

阿黴素（DOX）是一種用於治療癌症的化療過程中的學名藥。它以注射液或冷凍乾燥粉末形式經由周邊插入中心靜脈導管（PICC）或中心靜脈導管（CVC）進行靜脈注射。靜脈注射後，DOX 被酵素迅速消除，並在血漿中水解分解。它用於治療多種類型的癌症，包括乳腺癌、膀胱癌、卡波西氏肉瘤、淋巴瘤、腎母細胞瘤、非何杰金氏淋巴瘤和急性淋巴細胞白血病。

阿黴素市場趨勢：

癌症盛行率的增加主要推動了全球阿黴素市場的發展。這導致擴大使用 DOX 與其他化療藥物合併治療多種癌症。除此之外，對微創 (MI) 外科手術的需求不斷成長，以及無法接受重大手術的老年人口不斷增加，導致人們越來越傾向於將 DOX 作為癌症治療療法的一部分。各國政府也正在實施支持臨床腫瘤學技術進步的舉措，包括無靜脈注射治療和用於晶片生化分析的數位微流控技術。他們也正在進行提高癌症治療意識的計畫。因此，對 DOX 的需求顯著增加。此外，研究人員正在花費大量資金進行臨床試驗，以開發技術先進的 DOX 配方。此外，越來越多的併購以及先進形式 DOX 臨床試驗的合作夥伴關係預計將為未來幾年的市場創造積極的前景。

本報告回答的關鍵問題：

• 迄今為止，全球阿黴素市場表現如何，未來幾年將如何表現？
• COVID-19 對全球阿黴素市場有何影響？
• 主要區域市場有哪些？
• 基於應用程式的市場區隔是什麼？
• 基於配銷通路的市場區隔是什麼？
• 產業價值鏈的各個階段是什麼？
• 該行業的關鍵促進因素和挑戰是什麼？
• 全球阿黴素市場的結構如何？
• 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

• 研究目的
• 利害關係人
• 資料來源
  • 主要資源
  • 二手資料
• 市場預測
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第 3 章：執行摘要

第 4 章：簡介

• 概述
• 主要行業趨勢

第 5 章：全球阿黴素市場

• 市場概況
• 市場業績
• COVID-19 的影響
• 市場預測

第 6 章：市場區隔：按應用

• 乳癌
  • 市場走向
  • 市場預測
• 卵巢癌
  • 市場走向
  • 市場預測
• 多發骨髓瘤
  • 市場走向
  • 市場預測
• 卡波西氏肉瘤
  • 市場走向
  • 市場預測
• 白血病
  • 市場走向
  • 市場預測
• 骨肉瘤
  • 市場走向
  • 市場預測
• 子宮內膜癌
  • 市場走向
  • 市場預測
• 其他
  • 市場走向
  • 市場預測

第 7 章：市場區隔：按配銷通路

• 醫院和零售藥房
  • 市場走向
  • 市場預測
• 網路商店
  • 市場走向
  • 市場預測
• 其他
  • 市場走向
  • 市場預測

第 8 章：市場區隔：按地區

• 北美洲
  • 美國
  • 加拿大
• 亞太
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 印尼
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他
• 中東和非洲
  • 市場走向
  • 市場細分：按國家/地區
  • 市場預測

第 9 章：SWOT 分析

• 概述
• 優勢
• 弱點
• 機會
• 威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

• 概述
• 買家的議價能力
• 供應商的議價能力
• 競爭程度
• 新進入者的威脅
• 替代品的威脅

第 12 章：價格分析

第13章：競爭格局

• 市場結構
• 關鍵參與者
• 關鍵參與者簡介
  • Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
  • Baxter International Inc.
  • Cadila Pharmaceuticals
  • Cipla Inc.
  • Hikma Pharmaceuticals PLC
  • Meiji Holdings Co. Ltd.
  • Novartis AG
  • Pfizer Inc.

The global doxorubicin market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.33% during 2024-2032.

Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, Wilms' tumor, non-Hodgkin's lymphoma, and acute lymphocytic leukemia.

Doxorubicin Market Trends:

The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global doxorubicin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application and distribution channel.

Breakup by Application:

Breast Cancer

Ovarian Cancer

Multiple Myeloma

Kaposi Sarcoma

Leukemia

Bone Sarcoma

Endometrial Cancer

Others

Breakup by Distribution Channel:

Hospital and Retail Pharmacies

Online Stores

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report:

• How has the global doxorubicin market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global doxorubicin market?
• What are the key regional markets?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global doxorubicin market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Doxorubicin Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Application

• 6.1 Breast Cancer
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Ovarian Cancer
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Multiple Myeloma
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Kaposi Sarcoma
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Leukemia
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Bone Sarcoma
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Endometrial Cancer
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
• 6.8 Others
  • 6.8.1 Market Trends
  • 6.8.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital and Retail Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Online Stores
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
  • 13.3.2 Baxter International Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 Cadila Pharmaceuticals
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
  • 13.3.4 Cipla Inc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Hikma Pharmaceuticals PLC
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
  • 13.3.6 Meiji Holdings Co. Ltd.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Novartis AG
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Pfizer Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis

List of Figures

• Figure 1: Global: Doxorubicin Market: Major Drivers and Challenges
• Figure 2: Global: Doxorubicin Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Doxorubicin Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Doxorubicin Market: Breakup by Application (in %), 2023
• Figure 5: Global: Doxorubicin Market: Breakup by Distribution Channel (in %), 2023
• Figure 6: Global: Doxorubicin Market: Breakup by Region (in %), 2023
• Figure 7: Global: Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 8: Global: Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 9: Global: Doxorubicin (Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 10: Global: Doxorubicin (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 11: Global: Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 12: Global: Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 13: Global: Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 14: Global: Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 15: Global: Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 16: Global: Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 17: Global: Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 18: Global: Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 19: Global: Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 20: Global: Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 21: Global: Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 22: Global: Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 23: Global: Doxorubicin (Hospital and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 24: Global: Doxorubicin (Hospital and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 25: Global: Doxorubicin (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 26: Global: Doxorubicin (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: Global: Doxorubicin (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 28: Global: Doxorubicin (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 29: North America: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 30: North America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 31: United States: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 32: United States: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 33: Canada: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 34: Canada: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 35: Asia-Pacific: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 36: Asia-Pacific: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 37: China: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 38: China: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 39: Japan: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 40: Japan: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 41: India: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 42: India: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 43: South Korea: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 44: South Korea: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 45: Australia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 46: Australia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 47: Indonesia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 48: Indonesia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 49: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 50: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 51: Europe: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 52: Europe: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 53: Germany: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 54: Germany: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 55: France: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 56: France: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 57: United Kingdom: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 58: United Kingdom: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 59: Italy: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 60: Italy: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 61: Spain: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 62: Spain: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 63: Russia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 64: Russia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 65: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 66: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 67: Latin America: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 68: Latin America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 69: Brazil: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 70: Brazil: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 71: Mexico: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 72: Mexico: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 73: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 74: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 75: Middle East and Africa: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 76: Middle East and Africa: Doxorubicin Market: Breakup by Country (in %), 2023
• Figure 77: Middle East and Africa: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 78: Global: Doxorubicin Industry: SWOT Analysis
• Figure 79: Global: Doxorubicin Industry: Value Chain Analysis
• Figure 80: Global: Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Doxorubicin Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Doxorubicin Market Forecast: Breakup by Application (in Million US$), 2024-2032
• Table 3: Global: Doxorubicin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
• Table 4: Global: Doxorubicin Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Global: Doxorubicin Market: Competitive Structure
• Table 6: Global: Doxorubicin Market: Key Players